4e+40 Stock Overview
TRxADE HEALTH, Inc. operates as a health services information technology (IT) company in the United States.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
TRxADE HEALTH, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.86 |
52 Week High | US$20.01 |
52 Week Low | US$0.0015 |
Beta | 1.9 |
1 Month Change | 0% |
3 Month Change | 70.70% |
1 Year Change | -65.69% |
3 Year Change | -88.95% |
5 Year Change | n/a |
Change since IPO | -90.85% |
Recent News & Updates
Recent updates
Shareholder Returns
4e+40 | DE Healthcare Services | DE Market | |
---|---|---|---|
7D | 0% | 1.0% | -1.0% |
1Y | -65.7% | -23.9% | 2.0% |
Return vs Industry: 4E40 underperformed the German Healthcare Services industry which returned -10.2% over the past year.
Return vs Market: 4E40 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
4e+40 volatility | |
---|---|
4e+40 Average Weekly Movement | n/a |
Healthcare Services Industry Average Movement | 3.6% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 10.3% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4E40's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 4E40's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2010 | 34 | Suren Ajjarapu | www.trxadehealth.com |
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which offers price transparency, purchasing capabilities, and other value-added services; and offers patient centric telehealth services under the Bonum Health brand name.
TRxADE HEALTH, Inc. Fundamentals Summary
4e+40 fundamental statistics | |
---|---|
Market cap | €8.74m |
Earnings (TTM) | -€3.49m |
Revenue (TTM) | €8.83m |
1.0x
P/S Ratio-2.5x
P/E RatioIs 4e+40 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4e+40 income statement (TTM) | |
---|---|
Revenue | US$9.43m |
Cost of Revenue | US$4.16m |
Gross Profit | US$5.27m |
Other Expenses | US$9.00m |
Earnings | -US$3.73m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -2.99 |
Gross Margin | 55.91% |
Net Profit Margin | -39.55% |
Debt/Equity Ratio | 0% |
How did 4e+40 perform over the long term?
See historical performance and comparison